ZEUS TRIAL DEEP DIVE: WHAT DO THE RESULTS REALLY MEAN? What can ZEUS teach us about inflammation, cardiovascular outcomes and the next generation of clinical trials? Explore the evidence and future directions at #CVCT2026, Dec 7โ9 | Washington, DC: https://t.co/NhFw9qc2h9
#CVCT
If patients cannot understand clinical trial results, who is the evidence really serving? At #CVCT2026, patient advocates, trialists & journal editors explore plain-language summaries: https://t.co/VVtCNeYD9M
#PatientEngagement#ClinicalTrials
Heart failure devices: promising innovation, slow development, even slower adoption. Why? At #CVCT2026, the CVCT-THT joint symposium challenges how we design trials, generate evidence & bring device therapies to patients: https://t.co/VVtCNeYD9M
#HeartFailure#ClinicalTrials
What if the next cardiovascular breakthrough isn't a drug or device, but a better way to deliver care? At #CVCT2026, the CVCT- @NIH /NHLBI joint session asks: can implementation problems become rigorous clinical trials? https://t.co/VVtCNeYD9M
#ImplementationScience#CVCT
One global clinical trial. Multiple regulators. Different decisions. At #CVCT2026, experts examine the challenges of international evidence acceptance. Can we harmonize regulatory expectations without compromising scientific rigor? https://t.co/VVtCNeYD9M
#ClinicalTrials#CVCT
A positive clinical trial doesn't automatically change clinical guidelines. At #CVCT2026, trialists,journal editors & regulators debate how evidence becomes clinical recommendations. When is one positive trial enough? https://t.co/VVtCNeZaZk
#ClinicalTrials#EvidenceBasedMedicine
What happens when a clinical trial succeeds, but clinical practice doesn't change? At #CVCT2026, experts explore implementation science, payment reform & the barriers preventing evidence from reaching patients. https://t.co/VVtCNeZaZk
#ClinicalTrials
Clinical trials depend on collaboration. But collaboration depends on trust. At #CVCT2026: data access, scientific independence, transparency & the future of industry-academia partnerships. Join the debate: https://t.co/VVtCNeZaZk
#ClinicalTrials#ResearchIntegrity#CVCT
If CV prevention goes beyond ASCVD, shouldn't trial endpoints do the same? At #CVCT2026, the CVCTโ@DCRINews joint session explores heart failure, AF, diabetes & how to measure prevention in at-risk populations. Are we measuring the right outcomes?
https://t.co/VVtCNeZaZk
Can we repair the damaged heart? At #CVCT2026, experts explore cardiac regeneration, targeted biologics & emerging therapies. But should cardiology adopt accelerated pathways to bring regenerative treatments to patients? https://t.co/VVtCNeYD9M
#CVCT#ClinicalTrials
When is a surrogate endpoint enough to demonstrate clinical benefit? At #CVCT2026, experts confront the dilemma shaping the next generation of hypertrophic cardiomyopathy trials: surrogate endpoints vs. hard clinical outcomes. https://t.co/VVtCNeYD9M
#HCM#ClinicalTrials#CVCT
When the treatment landscape changes, clinical trials must evolve too. At #CVCT2026: cardiac amyloidosis, emerging therapies, new trial designs & the challenge of access. How do we turn innovation into meaningful patient care? https://t.co/VVtCNeZaZk
#ATTRCM#ClinicalTrials#CVCT
A trial can show that a treatment works.But does it tell us how patients actually feel? At #CVCT2026, the CVCTโHeart Failure Collaboratory session explores how to make patient-reported outcomes meaningful in clinical trials: https://t.co/VVtCNeZaZk
#HeartFailure#ClinicalResearch
A wearable can generate millions of data points. But when does a signal become clinical evidence?
At #CVCT2026, we follow the journey from wristโ endpoint โ regulation โ reimbursement โ clinical practice. Join the discussion: https://t.co/VVtCNeYD9M
#Wearables#DigitalHealth
#CVCT2026 What if the problem isnโt the therapy - but the trial designed to test it? Are standard RCT designs killing potentially effective hypertension therapies? And can cheap generic treatments coexist with innovative targeted ones? https://t.co/VVtCNeYD9M
#Hypertension
Gene therapy could transform CV medicine. But how do you design a trial for a therapy that may be irreversible? At #CVCT2026: patient selection, durability, safety & how much evidence is enough. Is it time to rethink the trial model? https://t.co/VVtCNeYD9M
#GeneTherapy#CVCT
#CVCT Great Debates
Some questions in clinical trials donโt need another lecture. They need a debate. At #CVCT2026, experts take opposing sides on endpoints, multi-organ composites, device vs drug trials & expanded MACE.
Join us Dec 7-9, Washington DC: https://t.co/VVtCNeYD9M
โณ DEADLINES EXTENDED | #CVCT2026
More time to bring your research to Washington, D.C.
๐ฌ Late-Breaking Clinical Trials
NEW deadline: October 8
๐ Poster Presentations
NEW deadline: October 15
Submit: https://t.co/NhFw9qcA6H
#CVCT#LBCT#Posters
LAST CALL | CVCT-LMIC Fellowship
Join the global clinical trials community at #CVCT2026 in Washington, DC
โ๏ธ Travel & accommodation covered
๐ Registration waived
๐ค Mentorship, masterclasses & networking
โณ Apply by October 8 here: https://t.co/0jwkfDEEil
#LMIC#ClinicalTrials
โณ FINAL CALL for Late-Breaking Clinical Trials at #CVCT2026
Bring your latest cardiovascular, kidney & metabolic trial evidence to the global CVCT community in Washington, D.C.
๐จ Deadline: October 1
Submit your LBCT here: https://t.co/rCQRzpIwUM
#ClinicalTrials#LBCT#CVCT